225 related articles for article (PubMed ID: 34262257)
41. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.
Sader HS; Huband MD; Castanheira M; Flamm RK
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652
[No Abstract] [Full Text] [Related]
42. The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.
MacGowan A; Tomaselli S; Noel A; Bowker K
J Antimicrob Chemother; 2017 Mar; 72(3):762-769. PubMed ID: 28039276
[TBL] [Abstract][Full Text] [Related]
43. Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014).
Sader HS; Castanheira M; Farrell DJ; Flamm RK; Jones RN
Diagn Microbiol Infect Dis; 2015 Dec; 83(4):389-94. PubMed ID: 26162518
[TBL] [Abstract][Full Text] [Related]
44. Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa.
Sader HS; Rhomberg PR; Huband MD; Critchley IA; Stone GG; Flamm RK; Jones RN
J Clin Microbiol; 2018 Jun; 56(6):. PubMed ID: 29563198
[TBL] [Abstract][Full Text] [Related]
45.
Yu W; Xiong L; Luo Q; Chen Y; Ji J; Ying C; Liu Z; Xiao Y
Front Cell Infect Microbiol; 2021; 11():780365. PubMed ID: 34900759
[TBL] [Abstract][Full Text] [Related]
46. In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis.
Nolan PJ; Jain R; Cohen L; Finklea JD; Smith TT
Diagn Microbiol Infect Dis; 2021 Feb; 99(2):115204. PubMed ID: 33152675
[TBL] [Abstract][Full Text] [Related]
47.
Stone GG; Newell P; Bradford PA
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29686147
[TBL] [Abstract][Full Text] [Related]
48. In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections.
Stone GG; Bradford PA; Yates K; Newell P
J Antimicrob Chemother; 2017 May; 72(5):1396-1399. PubMed ID: 28088768
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of Piperacillin/Sulbactam, Piperacillin/Tazobactam and Cefoperazone/Sulbactam Dosages in Gram-Negative Bacterial Bloodstream Infections by Monte Carlo Simulation.
Wang X; Xiong L; Yu W; Huang C; Ji J; Ying C; Liu Z; Chen Y; Xiao Y
Antibiotics (Basel); 2023 Feb; 12(2):. PubMed ID: 36830273
[TBL] [Abstract][Full Text] [Related]
50. Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection.
Berkhout J; Melchers MJ; van Mil AC; Seyedmousavi S; Lagarde CM; Schuck VJ; Nichols WW; Mouton JW
Antimicrob Agents Chemother; 2016 Jan; 60(1):368-75. PubMed ID: 26525790
[TBL] [Abstract][Full Text] [Related]
51. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
[TBL] [Abstract][Full Text] [Related]
52. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers.
Crandon JL; Nicolau DP
Antimicrob Agents Chemother; 2013 Jul; 57(7):3299-306. PubMed ID: 23650162
[TBL] [Abstract][Full Text] [Related]
53. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.
Kuti JL; Dandekar PK; Nightingale CH; Nicolau DP
J Clin Pharmacol; 2003 Oct; 43(10):1116-23. PubMed ID: 14517194
[TBL] [Abstract][Full Text] [Related]
54. [Efficacy and safety of colistimethate sodium in critical patients: an in vitro study by using of Monte Carlo simulation].
Pan A; Mei Q; Yang T; Gao X; Lu H; Ye Y; Li J; Liu B
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2017 May; 29(5):385-389. PubMed ID: 28524024
[TBL] [Abstract][Full Text] [Related]
55. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
[TBL] [Abstract][Full Text] [Related]
56. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa.
Crandon JL; Schuck VJ; Banevicius MA; Beaudoin ME; Nichols WW; Tanudra MA; Nicolau DP
Antimicrob Agents Chemother; 2012 Dec; 56(12):6137-46. PubMed ID: 22985878
[TBL] [Abstract][Full Text] [Related]
57. Performance of disc diffusion, MIC gradient tests and Vitek 2 for ceftolozane/tazobactam and ceftazidime/avibactam susceptibility testing of Pseudomonas aeruginosa.
Daragon B; Fournier D; Plésiat P; Jeannot K
J Antimicrob Chemother; 2021 Sep; 76(10):2586-2592. PubMed ID: 34245282
[TBL] [Abstract][Full Text] [Related]
58. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
Goff DA; Nicolau DP
Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
[TBL] [Abstract][Full Text] [Related]
59. Integrated Genome-Wide Analysis of an Isogenic Pair of
Huang W; Hamouche JE; Wang G; Smith M; Yin C; Dhand A; Dimitrova N; Fallon JT
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033143
[TBL] [Abstract][Full Text] [Related]
60. Emergence of a KPC-90 Variant that Confers Resistance to Ceftazidime-Avibactam in an ST463 Carbapenem-Resistant Pseudomonas aeruginosa Strain.
Tu Y; Wang D; Zhu Y; Li J; Jiang Y; Wu W; Li X; Zhou H
Microbiol Spectr; 2022 Feb; 10(1):e0186921. PubMed ID: 35019766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
